Novavax Inc. stocks have been trading up by 13.21 percent after promising vaccine data renewed investor confidence.
Click Here for a Millionaire's POV on Trading NVAX
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways For NVAX Traders
- Q1 2026 smashed expectations with EPS of $0.06 versus a forecast loss and revenue near $140M, driven by the Matrix-M licensing push and a fresh Pfizer agreement.
- Revenue is sharply lower versus the COVID peak, but NVAX nearly broke even on a GAAP basis while aggressively cutting costs and preserving cash.
- A new non-exclusive Matrix-M license with Pfizer plus multiple big-pharma MTAs and Sanofi royalties shift Novavax toward a partner-driven model.
- Activist holder Shah Capital, with roughly 9% of shares, is pushing for governance changes and potential strategic moves, sending the stock up more than 6% on that headline.
- B. Riley hiked its NVAX target to $18 and TD Cowen to $9, citing better fundamentals and a differentiated Nuvaxovid profile versus mRNA shots.
Live Update At 14:03:40 EDT: On Friday, May 08, 2026 Novavax Inc. stock [NASDAQ: NVAX] is trending up by 13.21%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
NVAX is finally showing traders what a real turnaround quarter looks like on paper. For Q1 2026, Novavax reported about $139.5M–$140M in revenue, crushing the roughly $80M consensus. The bottom line surprised even more: a loss of just $0.06 per share versus expectations for a $0.24 loss, and one report flags a positive $0.06 EPS print versus a forecast loss. Either way, the message is the same — NVAX out-executed the Street.
Under the hood, Novavax almost broke even on a GAAP basis while still dealing with a big comedown from prior COVID advance-purchase accounting. The company leans on a strong gross margin near 90%+ and has about $795M in cash and access to a $330M credit facility, which matters for a biotech that’s still burning money.
More Breaking News
- POET Stock Whipsaws As Leveraged ETF And U.S. Move Collide
- Remitly Global Stock Rises As Analysts Hike Price Targets
- CVSA Jumps As Covista Taps Google Cloud For AI Push
- RKT Stock Climbs As Earnings Beat And Housing Data Impress
On the chart, NVAX has ripped from the high-$7s in late April to above $10 on 2026/05/08. The daily candles show higher lows and a breakout through recent resistance. Intraday, the 5-minute chart is trending up all day, with tight pullbacks holding around $10.40–$10.50. For active trading, that intraday staircase pattern tells you dip buyers are in control — at least for now.
Why Traders Are Watching NVAX Right Now
The NVAX story in 2026 is no longer just “COVID laggard.” It’s a pivot play built around the Matrix-M adjuvant and a partner-first strategy. Q1 2026 numbers prove that. NVAX generated about $140M in revenue, well ahead of estimates, even though year-over-year revenue is down sharply as old non-cash APA close-outs roll off. Traders care less about the nostalgia of peak COVID and more about whether Novavax can replace that revenue stream with something durable. This quarter hints that it can.
The headline win is the new non-exclusive Matrix-M license with Pfizer. NVAX gets $30M upfront, up to $500M in milestones, plus royalties. That is serious validation. Add multiple new and expanded MTAs with top-10 pharma and oncology names, plus growing royalty and supply flows from Sanofi, and you get a clearer picture: Novavax wants to be a “picks-and-shovels” vaccine platform, not just a one-product COVID shop.
On the regulatory and competitive front, Sanofi data and a draft ICER review suggest Nuvaxovid may offer better tolerability than mRNA vaccines. For traders, that means NVAX can still carve out a niche in the seasonal COVID market, especially among patients who dislike mRNA side effects. Meanwhile, transferring Nuvaxovid’s Canadian marketing authorization to Sanofi fits the de-risking theme — let the big pharma experts sell, while Novavax collects royalties and trims sales costs.
Layer on top the activist angle: Shah Capital, owning about 9%, is voting against current board nominees and executive pay, calling out value destruction and a weak 2026 outlook. The stock popped more than 6% on that news. Activists do not show up if they see zero value. For NVAX traders, this is a core catalyst: pressure for a leaner board, deeper cost cuts, maybe even a sale process. Combine that with B. Riley’s new $18 target and TD Cowen’s higher $9 target, and NVAX is firmly back on watchlists.
Conclusion
For traders, NVAX is shifting from a broken COVID story into a complex but tradable turnaround. The Q1 2026 print — around $139.5M–$140M in revenue and a far narrower loss than feared — shows real operating discipline. Nearly breakeven GAAP results, aggressive expense cuts, and roughly $795M in cash plus a $330M credit facility give Novavax time to execute. That runway matters when you’re playing a volatile biotech name.
The strategic pivot is clear. NVAX is monetizing Matrix-M through Pfizer, Sanofi, and other top-tier pharma and oncology partners, while still nurturing its own pipeline in C. difficile, shingles, and RSV. That adds optionality beyond COVID and helps justify why Wall Street is starting to lift price targets. At the same time, traders should not ignore the risks: year-over-year revenue is still down sharply, the balance sheet carries negative equity, and activist pressure signals serious concern about long-term planning.
This is exactly the kind of setup active traders at timothysykes.com look for: a beaten-down chart with fresh catalysts, improving numbers, and plenty of volatility. As Tim Sykes always says, “Trade the price action, not the hype.” That lines up with the broader trading mindset: focus on what the market is actually doing, not on the story you want to believe. As Tim Bohen, lead trainer with StocksToTrade says, “A good trade setup checks all the boxes—volume, trend, catalyst. Don’t trade if you’re missing pieces of the puzzle.”. For NVAX, that means respecting the bullish trend, watching key support around recent breakout levels, and being ready to cut losses fast if the story or the chart cracks. This article is for educational and research purposes only and is not investment advice.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.